Fariba Pfitzner
Child & Adolescent Psychiatry · Scottsdale, AZNPI 1053511923
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 179 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 20.1% — the pattern of someone who eats at a lot of different presentations.
Across 179 payments — averaging $27.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$976
- AbbVie$621
- Otsuka America Pharmaceutical, Inc.$516
- Johnson & Johnson$503
- Alkermes, Inc.$476
- Sunovion Pharmaceuticals Inc.$279
- plus $1K from 19 others
What the payments were for
- Food & beverage$4,82699%
- Education$241%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 27 | $976 |
| AbbVie | 22 | $621 |
| Otsuka America Pharmaceutical, Inc. | 16 | $516 |
| Johnson & Johnson | 17 | $503 |
| Alkermes, Inc. | 14 | $476 |
| Sunovion Pharmaceuticals Inc. | 28 | $279 |
| Teva Pharmaceuticals USA, Inc. | 11 | $262 |
| Novo Nordisk | 2 | $243 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $228 |
| Axsome Therapeutics, Inc. | 2 | $147 |
| Neos Therapeutics, LP | 5 | $96 |
| Eisai Inc. | 4 | $82 |
| Alfasigma USA, Inc. | 3 | $72 |
| Vanda Pharmaceuticals Inc. | 2 | $46 |
| Vertical Pharmaceuticals, LLC | 2 | $41 |
| Neurocrine Biosciences, Inc. | 1 | $40 |
| Indivior Inc. | 2 | $38 |
| Supernus Pharmaceuticals, Inc. | 2 | $34 |
| Neuronetics, Inc. | 1 | $30 |
| Ironshore Pharmaceuticals Inc. | 1 | $24 |
| Edwards Lifesciences | 1 | $21 |
| Corium, LLC | 1 | $20 |
| Shire North American Group Inc | 1 | $20 |
| Arbor Pharmaceuticals, Inc. | 1 | $18 |
| Noven Therapeutics, LLC | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,850 in reported general payments places this provider in the 85th percentile of 80 child & adolescent psychiatry providers in Arizona.
See all child & adolescent psychiatry providers in Arizona →
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Methylphenidate Er (La)Methylphenidate Hcl | 12 | $856 |
| Methylphenidate Hcl | 12 | $136 |
Paid to pharmacies, not to this prescriber.
Other child & adolescent psychiatry in Scottsdale
- Ramiro GuillenScottsdale$31K
- Linda KalivasScottsdale$13K
- Palpu HazelScottsdale$13K
- Kenneth ZwierScottsdale$7K
- Roya KarbakhshScottsdale$6K
- Shaili PatelScottsdale$3K
- Marilyn Pupo GuillenScottsdale$2K
- Lilia Romero-BoschScottsdale$1K
- Patricia Tagle-LevyScottsdale$732
- Sandeep KaurScottsdale$626
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.